Brief: Immutep And Dr. Reddy's Enters Into Strategic Collaboration For Commercialisation Of An Innovative Oncology Drug, Eftilagimod Alfa
08/12/2025 13:06
Dec 8 (Reuters) - Immutep Ltd IMM.AX: IMMUTEP AND DR. REDDY’S ENTERS INTO STRATEGIC COLLABORATION FOR COMMERCIALISATION OF AN INNOVATIVE ONCOLOGY DRUG, EFTILAGIMOD ALFA IMMUTEP LTD - TO RECEIVE USD 20 MILLION UPFRONT AND UP TO USD 349.5 MILLION IMMUTEP LTD - DR. REDDY'S RECEIVES EXCLUSIVE RIGHTS FOR EFTILAGIMOD ALFA IN ALL COUNTRIES OUTSIDE NORTH AMERICA, EUROPE, JAPAN, & GREATER CHINA Source text: ID:nGNXbkkw8t Further company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))